Pedro Genaro Delgado-Guillena

Pedro Genaro Delgado-Guillena

Auto-generated profile, based on publicly available information

Pedro Genaro Delgado-Guillena

Department of Gastroenterology. Hospital General de Granollers, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2025 in Endoscopy
Verified
Journal Article
Closed access
PDF file
MAMiguel Areia
Miguel Areia
GEGianluca Esposito
Gianluca Esposito
PLPhilippe Leclercq
Philippe Leclercq
MRMarcin Romańczyk
Marcin Romańczyk
JZJasmin Zessner-Spitzenberg
Jasmin Zessner-Spitzenberg
AVAndrei Voiosu
Andrei Voiosu
Quality markers and patient experience should be implemented to ensure standardization of practice across upper gastrointestinal (UGI) endoscopy procedures. The set benchmarks ensure high quality procedures are delivered and linked to measurable outcomes. In 2016, the European Society of Gastrointestinal Endoscopy (ESGE), via its Quality Improvement Committee’s UGI Working Group, set a first list of performance measures, including major (key) and minor performance indicators. This paper provides an update on those performance measures, considering the latest literature. Patients referred for a UGI endoscopy should have an appropriate indication and be fasting for ≥ 2 hours for liquids and ≥ 6 hours for solids. For a diagnostic UGI endoscopy, patients should have an allocated time slot of ≥ 20 minutes; adequate reporting should include a mucosal visibility score according to one of the available standardized and validated scales; adequate photodocumentation should include relevant normal anatomical landmarks and all abnormal findings; adequate inspection should include the esophagus, stomach, and duodenum, and should last ≥ 7 minutes from intubation to extubation; adequate terminology should include the description of any abnormal finding according to the available standardized and validated classifications. For patients with nondysplastic Barrett’s esophagus (BE) undergoing surveillance UGI endoscopy, an adequate inspection should take ≥ 1 minute/cm of circumferential extent of Barrett’s epithelium and include the use of chromoendoscopy (acetic acid and/or virtual); biopsies should be taken according to the Seattle protocol. Adequate inspection for a diagnostic UGI endoscopy in patients with a history of ear, nose, and throat, or lung tumors treated with curative intent should include the use of virtual chromoendoscopy. Adequate diagnostic UGI endoscopy for patients evaluated for their risk of gastric cancer should include biopsies taken according to the ESGE management of precancerous conditions and lesions in the stomach (MAPS) guideline. Adequate safety after a therapeutic UGI endoscopy should be assessed by monitoring the incidence of complications. Patients undergoing a diagnostic UGI endoscopy should have their experience measured using a validated scale, to promote a patient-centered and quality-driven environment. Patients with nondysplastic BE or gastric precancerous conditions in an endoscopic surveillance program should be monitored for guideline interval adherence.

1 November 2020 in United European Gastroenterology Journal
Verified
Journal Article
Open access
PDF file
IRIago Rodríguez-Lago
Iago Rodríguez-Lago
JHJavier Del Hoyo
Javier Del Hoyo
APAlexandre Pérez-Girbés
Alexandre Pérez-Girbés
AGAlejandro Garrido-Marín
Alejandro Garrido-Marín
MCMaría José Casanova
María José Casanova
JGJavier P Gisbert
Javier P Gisbert
Background: There is limited evidence on the effectiveness of biological therapy in stricturing complications in patients with Crohn’s disease.Aim: The study aims to determine the effectiveness of anti‐tumor necrosis factor (TNF) agents in Crohn’s disease complicated with symptomatic strictures.Methods: In this multicentric and retrospective study, we included adult patients with symptomatic stricturing Crohn’s disease receiving their first anti‐TNF therapy, with no previous history of biological, endoscopic or surgical therapy. The effectiveness of the anti‐TNF agent was defined as a composite outcome combining steroid‐free drug persistence with no use of new biologics or immunomodulators, hospital admission, surgery or endoscopic therapy during follow‐up.Results: Overall, 262 patients with Crohn’s disease were included (53% male; median disease duration, 35 months, 15% active smokers), who received either infliximab (N = 141, 54%) or adalimumab (N = 121, 46%). The treatment was effective in 87% and 73% of patients after 6 and 12 months, respectively, and continued to be effective in 26% after a median follow‐up of 40 months (IQR, 19–85). Nonetheless, 15% and 21% of individuals required surgery after 1 and 2 years, respectively, with an overall surgery rate of 32%. Postoperative complications were identified in 15% of patients, with surgical site infection as the most common. Starting anti‐TNF therapy in the first 18 months after the diagnosis of Crohn’s disease or the identification of stricturing complications was associated with a higher effectiveness (HR 1.62, 95% CI 1.18–2.22; and HR 1.55, 95% CI 1.1–2.23; respectively). Younger age, lower albumin levels, strictures located in the descending colon, concomitant aminosalicylates use or presence of lymphadenopathy were associated with lower effectiveness.Conclusions: Anti‐TNF agents are effective in approximately a quarter of patients with Crohn’s disease and symptomatic intestinal strictures, and 68% of patients are free of surgery after a median of 40 months of follow‐up. Early treatment and some potential predictors of response were associated with treatment success in this setting.

1 August 2019 in Digestive and Liver Disease
Verified
Journal Article
Closed access
PGPedro Genaro Delgado Guillena
Pedro Genaro Delgado Guillena
VAVíctor Jair Morales Alvarado
Víctor Jair Morales Alvarado
MRMireya Jimeno Ramiro
Mireya Jimeno Ramiro
JCJoaquim Rigau Cañardo
Joaquim Rigau Cañardo
CSConsuelo Ramírez Salazar
Consuelo Ramírez Salazar
GFGloria Fernández-Esparrach
Gloria Fernández-Esparrach

20 December 2024 in Gut
Verified
Journal Article
Open access
PDF file
JGJavier P Gisbert
Javier P Gisbert
MDMaría G Donday
María G Donday
SRSabino Riestra
Sabino Riestra
ALAlfredo J Lucendo
Alfredo J Lucendo
JBJosé-Manuel Benítez
José-Manuel Benítez
MCMaría Chaparro
María Chaparro
Background and objectives Primary objectives: to compare the rates of sustained clinical remission at 12 months in patients treated with antitumour necrosis factor (anti-TNF) and immunomodulators who withdraw anti-TNF treatment versus those who maintain it. Secondary objectives: to evaluate the effect of anti-TNF withdrawal on relapse-free time, endoscopic and radiological activity, safety, quality of life and work productivity; and to identify predictive factors for relapse. Design Prospective, quadruple-blind, multicentre, randomised, controlled trial. Patients with ulcerative colitis or Crohn’s disease in clinical remission for >6 months and absence of severe endoscopic (and radiological in Crohn’s disease) lesions were randomised to maintain anti-TNF treatment (maintenance arm (MA)) or to withdraw it (withdrawal arm (WA)). All patients maintained immunomodulators. Patients were followed-up until month 12 or up to clinical relapse. Results One-hundred forty patients were randomised: 70 were allocated to the MA and 70 to the WA. The proportion of patients with sustained clinical remission at 12 months was similar in the MA and WA: 59/70 (84%), 95% CI=74% to 92% versus 53/70 (76%), 95% CI=64% to 85%. The proportion of patients with significant endoscopic lesions at the end of follow-up was 8.5% in the MA and 19% in the WA (p=0.1); a higher proportion of patients had faecal calprotectin >250 µg/g at the end of follow-up in the WA (p=0.01). The same percentage of patients in both groups had at least one adverse event (69%). The proportion of patients with serious adverse events was also similar in both groups (4% in MA vs 7% in WA). Conclusion Anti-TNF withdrawal in selected patients with IBD in clinical, endoscopic and radiological remission has no impact on sustained clinical remission at 1 year although objective markers of activity were higher in patients who withdrew treatment. Trial registration number https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001410-10 https://clinicaltrials.gov/study/NCT02994836

26 September 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MGMaría José García
María José García
MRMontserrat Rivero
Montserrat Rivero
JMJose Miranda-Bautista
Jose Miranda-Bautista
IBIria Bastón-Rey
Iria Bastón-Rey
FMFrancisco Mesonero
Francisco Mesonero
OGon behalf of the Young Group of GETECCU
on behalf of the Young Group of GETECCU
Background: The impact of biologics on the risk of postoperative complications (PC) in inflammatory bowel disease (IBD) is still an ongoing debate. This lack of evidence is more relevant for ustekinumab and vedolizumab. Aims: To evaluate the impact of biologics on the risk of PC. Methods: A retrospective study was performed in 37 centres. Patients treated with biologics within 12 weeks before surgery were considered “exposed”. The impact of the exposure on the risk of 30-day PC and the risk of infections was assessed by logistic regression and propensity score-matched analysis. Results: A total of 1535 surgeries were performed on 1370 patients. Of them, 711 surgeries were conducted in the exposed cohort (584 anti-TNF, 58 vedolizumab and 69 ustekinumab). In the multivariate analysis, male gender (OR: 1.5; 95% CI: 1.2–2.0), urgent surgery (OR: 1.6; 95% CI: 1.2–2.2), laparotomy approach (OR: 1.5; 95% CI: 1.1–1.9) and severe anaemia (OR: 1.8; 95% CI: 1.3–2.6) had higher risk of PC, while academic hospitals had significantly lower risk. Exposure to biologics (either anti-TNF, vedolizumab or ustekinumab) did not increase the risk of PC (OR: 1.2; 95% CI: 0.97–1.58), although it could be a risk factor for postoperative infections (OR 1.5; 95% CI: 1.03–2.27). Conclusions: Preoperative administration of biologics does not seem to be a risk factor for overall PC, although it may be so for postoperative infections.

1 November 2017 in Gastroenterología y Hepatología
Verified
Journal Article
Closed access
HCHenry Córdova
Henry Córdova
CSCristina Sánchez-Montes
Cristina Sánchez-Montes
PDPedro G. Delgado-Guillena
Pedro G. Delgado-Guillena
VMVictor J. Morales
Victor J. Morales
OSOriol Sendino
Oriol Sendino
GFGloria Fernández-Esparrach
Gloria Fernández-Esparrach